Peter Hecht - Cyclerion Therapeutics CEO Director
| CYCN Stock | USD 2.57 0.04 1.58% |
Insider
Peter Hecht is CEO Director of Cyclerion Therapeutics
| Age | 60 |
| Address | 245 First Street, Riverview II, Cambridge, MA, United States, 02142 |
| Phone | 857 327 8778 |
| Web | https://www.cyclerion.com |
Peter Hecht Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Hecht against Cyclerion Therapeutics stock is an integral part of due diligence when investing in Cyclerion Therapeutics. Peter Hecht insider activity provides valuable insight into whether Cyclerion Therapeutics is net buyers or sellers over its current business cycle. Note, Cyclerion Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cyclerion Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Hecht over three months ago Acquisition by Peter Hecht of 15000 shares of Cyclerion Therapeutics subject to Rule 16b-3 | ||
Peter Hecht over six months ago Acquisition by Peter Hecht of 430000 shares of Cyclerion Therapeutics at 1.21 subject to Rule 16b-3 | ||
Peter Hecht over six months ago Acquisition by Peter Hecht of 15000 shares of Cyclerion Therapeutics subject to Rule 16b-3 | ||
Peter Hecht over six months ago Acquisition by Peter Hecht of 351037 shares of Cyclerion Therapeutics subject to Rule 16b-3 |
Cyclerion Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5025) %, meaning that it created substantial loss on money invested by shareholders. Cyclerion Therapeutics' management efficiency ratios could be used to measure how well Cyclerion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of November 2024, Return On Tangible Assets is likely to drop to -1.65. In addition to that, Return On Capital Employed is likely to grow to -0.81. At this time, Cyclerion Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 11th of November 2024, Asset Turnover is likely to grow to 0.02, while Total Assets are likely to drop about 12.7 M.Similar Executives
| Found 10 records | INSIDER Age | ||
| Mark Dudley | Instil Bio | N/A | |
| Jane Springer | Hoth Therapeutics | 39 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Timothy Moore | Instil Bio | 63 | |
| Sandeep MD | Instil Bio | 55 | |
| Stefanie Johns | Hoth Therapeutics | 39 | |
| David Briones | Hoth Therapeutics | 48 | |
| Sumita JD | Instil Bio | 50 | |
| Bronson Crouch | Instil Bio | 51 | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.47 |
Cyclerion Therapeutics Leadership Team
Elected by the shareholders, the Cyclerion Therapeutics' board of directors comprises two types of representatives: Cyclerion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclerion. The board's role is to monitor Cyclerion Therapeutics' management team and ensure that shareholders' interests are well served. Cyclerion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclerion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Milne, Senior Innovation | ||
| Cheryl Gault, Chief Officer | ||
| Jessica Rennekamp, Associate Communications | ||
| Regina Graul, President | ||
| Christopher Winrow, Sr Lead | ||
| Jennifer Chickering, Director Strategy | ||
| Rhonda Chicko, Chief Officer | ||
| Peter Hecht, CEO Director | ||
| Anjeza Gjino, CFO Sec |
Cyclerion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclerion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 1.78 M | ||||
| Shares Outstanding | 2.52 M | ||||
| Shares Owned By Insiders | 21.90 % | ||||
| Shares Owned By Institutions | 40.69 % | ||||
| Number Of Shares Shorted | 12.03 K | ||||
| Price To Earning | (0.59) X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 55.50 X |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
| 0.6 | A | Agilent Technologies Earnings Call Tomorrow | PairCorr |
| 0.41 | VCYT | Veracyte | PairCorr |
| 0.31 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.